Pharvaris (NASDAQ:PHVS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Pharvaris (NASDAQ:PHVS) from a sell rating to a hold rating in a report published on Saturday.

A number of other brokerages have also recently commented on PHVS. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Morgan Stanley upped their target price on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research report on Wednesday, December 3rd. Finally, Leerink Partners set a $38.00 price objective on Pharvaris in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.56.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $26.42 on Friday. The company has a fifty day simple moving average of $26.01 and a 200-day simple moving average of $24.00. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.08. Equities research analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Pharvaris in the fourth quarter valued at $139,000. PSP Research LLC acquired a new position in shares of Pharvaris during the 4th quarter worth $569,000. UBS Group AG increased its holdings in shares of Pharvaris by 5.3% in the 4th quarter. UBS Group AG now owns 137,734 shares of the company’s stock valued at $3,822,000 after purchasing an additional 6,982 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Pharvaris by 247.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,438 shares of the company’s stock valued at $290,000 after purchasing an additional 7,438 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Pharvaris during the fourth quarter worth about $110,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.